Viridian Therapeutics disclosed top-line Phase III results for elegrobart (VRDN-003), an insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody in active thyroid eye disease. Patients received subcutaneous dosing at every-four-weeks or every-eight-weeks intervals versus placebo, with the primary endpoint focused on proptosis response rate. The company reported that elegrobart met the primary endpoint with high statistical significance in the monthly-dosing cohort, including a responder rate of 54% versus 18% with placebo. Investors remained divided given cross-trial expectations versus Amgen’s teprotumumab (Tepezza) and questions around commercial competitiveness for an injectable regimen. Viridian also framed the trial as its largest pivotal study in active TED, with supportive secondary outcomes including improvements in diplopia and proptosis change metrics.